Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study

Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study

Abstract Highly selective inhibitors of cyclin-dependent kinase 4 and 6 (CDK4/6is) have emerged as a standart of care for first- and second-line therapies in combination with endocrine therapy (ET) for HR+/HER2- metastatic breast cancer (MBC) patients. It has been reported that combination therapy i...

Full description

Saved in:
Bibliographic Details
Main Authors: Seda Kahraman, Mutlu Hizal, Burcin Cakan Demirel, Deniz Can Guven, Ozge Gumusay, Basak Oyan Uluc, Ertugrul Bayram, Burcu Gulbagci, Alper Yasar, Sena Ece Davarci, Eda Eylemer Mocan, Omer Acar, Deniz Isik, Esra Aydin, Yusuf Karakas, Melike Ozcelik, Murat Keser, Sadi Kerem Okutur, Onder Eren, Serkan Menekse, Dincer Aydin, Funda Yilmaz, Ozlem Dogan, Gulhan Ozkanli, Hakan Yucel, Veli Sunar, Musa Baris Aykan, Ozlem Ozdemir, Berna Bozkurt Duman, Merve Keskinkilic, Teoman Sakalar, Ali Inal, Muge Karaoglanoglu, Asude Aksoy, Muhammed Muhiddin Er, Nazim Serdar Turhal, Nurhan Onal Kalkan, Mehmet Ali Nahit Sendur
Format: Article
Language:English
Published: BMC 2024-12-01
Series:BMC Cancer
Subjects:
CDK 4/6 inhibitors
Metastatic breast cancer
Geriatric population
Online Access:https://doi.org/10.1186/s12885-024-13357-5
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items